One of the advantages of a MAB listing is the generation of liquidity that allows the company to grow inorganically. As proof of this, in the last year we have seen several companies from very different sectors listed on the MAB that have made acquisitions, such as Clerph, Inkemia, or Bionaturis.
Clerhp buys Construcciones Guamora Paraguay
Clerhp was listed on the Mab in March this year and at the end of April, it announced the purchase of a company in Paraguay, Construcciones Guamora Paraguay.
This engineering company saw Mab as an opportunity to advance its expansion strategy, focused on countries with high growth potential, such as Latin America.
Prior to the Mab listing, the company conducted a capital increase 1.05m, which will allow it to address its expansion plan "organically", through the opening of new subsidiaries. It is currently present in Spain, Bolivia and Brazil.
Now, with the Mab listing, the company is looking to grow inorganically, through the purchase of small companies, as well as through alliances with local engineering firms that are well positioned in their home markets.
The first purchase it has made is an engineering company in Paraguay, which allows it to enter this country, one of the strategic markets in its expansion policy. The other countries Clerhp has its eye on are Bolivia and Brazil.
Inkemia : enters Pharmamel, participates in the capital increase of Mind the Byte and acquires a stake of €145,000 in CIMER S.A.
Inkemia was floated on Mab in 2012 and has been very active ever since. In addition to creating several startups, through its subsidiary IUCT Emprén, it has participated in several startups.
Last year Inkemia entered into Pharmamela spin-off of the University of Granada founded in 2014 and focused on the development of cosmetic and health products in the field of cellular ageing and their application to the skin.
The entry was made by leading the company's capital increase.
Inkemia also participated in the capital increase made by MindTheByte, a company specialising in the development and provision of services through scientific cloud solutions and data analysis.
Inkemia covered 10% of the planned €100,000 increase.
This year 2016, Inkemia has acquired a stake of €145,000 in CIMER S.A. This stake has been made through a loan of €145,000 that can be converted into shares in the company Centro Internacional de Medicina Regenerativa Biomed (CIMER).
In addition to Inkemia, as we mentioned in a post a few weeks ago, another biotech company on the Mab, Bionaturis, has also recently bought a company, BBD BIOPHENIX S. L.
Other posts that may interest you
Clerhp structures exits the mab up 10.24%
TECNOQUARK goes public on the MAB to finance growth
Oryzon genomics floats on the MAB
If you are thinking of going public on Mab, contact us. Abra.Invest has an expert team that can help you to make your Mab listing a success. Call us on + 34 946424142 or fill in the contact form.
